Famotidine: A supplemental drug for the treatment of schizophrenia

P. N. Dannon; E. Lepkifker; I. Iancu; R. Ziv; N. Horesh; M. Kotler

doi:10.1016/S0924-9338(97)83302-0

Famotidine: A supplemental drug for the treatment of schizophrenia

P. N. Dannon
, E. Lepkifker
, I. Iancu
, R. Ziv
, N. Horesh
, M. Kotler

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In an open-label study, famotidine was added to the regular neuroleptic regimen of 11 schizophrenic patients for 4 weeks. Each patient was scored weekly with SAPS, SANS. CGI and HAM-D-17 scales. The results suggest that famotidine is indeed effective as an adjunctive drug to neuroleptics in the treatment of schizophrenia.

Original language	English
Pages (from-to)	263-264
Number of pages	2
Journal	European Psychiatry
Volume	12
Issue number	5
DOIs	https://doi.org/10.1016/S0924-9338(97)83302-0
State	Published - 1 Jan 1997
Externally published	Yes

Keywords

Famotidine
H-receptor antagonists
Neuroleptics
Schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1016/S0924-9338(97)83302-0

Cite this

@article{15de64f0f4aa4ee187fbe8c1b4468d1e,

title = "Famotidine: A supplemental drug for the treatment of schizophrenia",

abstract = "In an open-label study, famotidine was added to the regular neuroleptic regimen of 11 schizophrenic patients for 4 weeks. Each patient was scored weekly with SAPS, SANS. CGI and HAM-D-17 scales. The results suggest that famotidine is indeed effective as an adjunctive drug to neuroleptics in the treatment of schizophrenia.",

keywords = "Famotidine, H-receptor antagonists, Neuroleptics, Schizophrenia",

author = "Dannon, \{P. N.\} and E. Lepkifker and I. Iancu and R. Ziv and N. Horesh and M. Kotler",

year = "1997",

month = jan,

day = "1",

doi = "10.1016/S0924-9338(97)83302-0",

language = "English",

volume = "12",

pages = "263--264",

journal = "European Psychiatry",

issn = "0924-9338",

publisher = "Cambridge University Press",

number = "5",

}

TY - JOUR

T1 - Famotidine

T2 - A supplemental drug for the treatment of schizophrenia

AU - Dannon, P. N.

AU - Lepkifker, E.

AU - Iancu, I.

AU - Ziv, R.

AU - Horesh, N.

AU - Kotler, M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - In an open-label study, famotidine was added to the regular neuroleptic regimen of 11 schizophrenic patients for 4 weeks. Each patient was scored weekly with SAPS, SANS. CGI and HAM-D-17 scales. The results suggest that famotidine is indeed effective as an adjunctive drug to neuroleptics in the treatment of schizophrenia.

AB - In an open-label study, famotidine was added to the regular neuroleptic regimen of 11 schizophrenic patients for 4 weeks. Each patient was scored weekly with SAPS, SANS. CGI and HAM-D-17 scales. The results suggest that famotidine is indeed effective as an adjunctive drug to neuroleptics in the treatment of schizophrenia.

KW - Famotidine

KW - H-receptor antagonists

KW - Neuroleptics

KW - Schizophrenia

UR - https://www.scopus.com/pages/publications/0030835767

U2 - 10.1016/S0924-9338(97)83302-0

DO - 10.1016/S0924-9338(97)83302-0

M3 - Article

AN - SCOPUS:0030835767

SN - 0924-9338

VL - 12

SP - 263

EP - 264

JO - European Psychiatry

JF - European Psychiatry

IS - 5

ER -

Famotidine: A supplemental drug for the treatment of schizophrenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this